Edition:
United Kingdom

Aceto Corp (ACET.OQ)

ACET.OQ on NASDAQ Stock Exchange Global Select Market

2.51USD
20 Apr 2018
Change (% chg)

$-0.15 (-5.64%)
Prev Close
$2.66
Open
$2.72
Day's High
$2.72
Day's Low
$2.50
Volume
516,346
Avg. Vol
153,672
52-wk High
$17.10
52-wk Low
$2.50

Chart for

About

Aceto Corporation (Aceto) is engaged in the marketing, sales and distribution of finished dosage form generic pharmaceuticals, nutraceutical products, pharmaceutical active ingredients and intermediates, specialty performance chemicals inclusive of agricultural intermediates and agricultural protection products. The Company's... (more)

Overall

Beta: 1.43
Market Cap(Mil.): $349.27
Shares Outstanding(Mil.): 30.11
Dividend: 0.06
Yield (%): 2.24

Financials

  ACET.OQ Industry Sector
P/E (TTM): 33.80 30.95 32.74
EPS (TTM): 0.34 -- --
ROI: 1.81 14.84 14.38
ROE: 3.19 16.34 16.07

BRIEF-Aceto To Appeal U.S. Government Ruling Regarding Certain Lucid Pharma Contracts

* ACETO TO APPEAL U.S. GOVERNMENT RULING REGARDING CERTAIN LUCID PHARMA CONTRACTS

27 Feb 2018

BRIEF-Aceto Appoints Edward Borkowski Chief Financial Officer

* ACETO CORP - APPOINTS EDWARD BORKOWSKI AS CFO EFFECTIVE FEB 21, 2018 Source text for Eikon: Further company coverage:

16 Feb 2018

BRIEF-Aceto Subsidiary, Rising Pharmaceuticals, Launches Atenolol Tablets, 25Mg, 50Mg And 100Mg

* ACETO SUBSIDIARY, RISING PHARMACEUTICALS, LAUNCHES ATENOLOL TABLETS, 25MG, 50MG AND 100MG

07 Feb 2018

BRIEF-Aceto Q2 Loss Per Share $0.39

* IN QUARTER, NET LOSS INCLUDES $13.9 MILLION OF ADDITIONAL INCOME TAX EXPENSE ASSOCIATED WITH TAX CUTS AND JOBS ACT

01 Feb 2018

BRIEF-Aceto's Unit Launches Efavirenz Capsules, 50Mg, 200Mg

* ACETO SUBSIDIARY, RISING PHARMACEUTICALS, LAUNCHES EFAVIRENZ CAPSULES, 50MG AND 200MG

02 Jan 2018

BRIEF-Aceto reports fiscal 2018 first quarter results

* Q1 earnings per share view $0.29 -- Thomson Reuters I/B/E/S

02 Nov 2017

BRIEF-Aceto corp CFO Douglas Roth notifies co he will retire effective March 31, 2018​

* Says on October 26, Douglas Roth, Chief Financial Officer of Aceto Corporation notified company that he will retire effective March 31, 2018​ Source text : ( http://bit.ly/2yQZ0rq ) Further company coverage:

27 Oct 2017

BRIEF-ACETO SAYS UNIT, RISING PHARMACEUTICALS, LAUNCHES SERTRALINE ORAL SOLUTION, 20MG/ML

* ACETO SUBSIDIARY, RISING PHARMACEUTICALS, LAUNCHES SERTRALINE ORAL SOLUTION, 20MG/ML Source text for Eikon: Further company coverage:

24 Oct 2017

Earnings vs. Estimates